Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
23
APXZF Quote, Financials, Valuation and Earnings
Last price:
$4.30
Seasonality move
:
0%
Day range:
$4.30 - $4.30
52-week range:
$4.30 - $4.30
Dividend yield:
0%
P/E ratio:
705.48x
P/S ratio:
9.92x
P/B ratio:
3.43x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$301M
Revenue:
$26M
EPS (TTM):
$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Carasent AB has -- downside to fair value with a price target of -- per share.
APXZF vs. S&P 500
-
Over the past 5 trading days, Carasent AB has underperformed the S&P 500 by -1.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Carasent AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Carasent AB has grown year-over-year revenues for 26 quarters straight. In the most recent quarter Carasent AB reported revenues of $8.6M.
Earnings Growth
-
Carasent AB has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Carasent AB reported earnings per share of $0.02.
Enterprise value:
286.4M
EV / Invested capital:
3.13x
Price / LTM sales:
9.92x
EV / EBIT:
--
EV / Revenue:
9.12x
PEG ratio (5yr expected):
-0.37x
EV / Free cash flow:
-144.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
48.63x
Gross Profit (TTM):
$4.9M
Return On Assets:
0.42%
Net Income Margin (TTM):
1.41%
Return On Equity:
0.5%
Return On Invested Capital:
0.48%
Operating Margin:
10.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $22.6M | $24.7M | $31.4M | $6.2M | $8.6M | |
| Gross Profit | $1.8M | $2.7M | $4.9M | $833K | $1.9M | |
| Operating Income | -$2.9M | -$2.9M | -$361.7K | -$777.9K | $868.3K | |
| EBITDA | $1.6M | $2.6M | $5.9M | $644.4K | $2.6M | |
| Diluted EPS | -$0.08 | -$0.01 | $0.01 | -$0.00 | $0.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $105.8M | $71.8M | $64.7M | $40.8M | $26.6M | |
| Total Assets | $150.6M | $124.5M | $125.4M | $103.9M | $104.8M | |
| Current Liabilities | $6.7M | $7.9M | $19.8M | $9.9M | $12.1M | |
| Total Liabilities | $16.6M | $10.9M | $25.4M | $14.1M | $17.2M | |
| Total Equity | $134M | $113.7M | $100.1M | $89.8M | $87.6M | |
| Total Debt | $9M | $1.8M | $4.9M | $4.2M | $3.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $382K | $3.6M | $2.1M | -$225.9K | $350K | |
| Cash From Investing | -$9.8M | -$4.5M | -$4.1M | -$885.3K | -$1.2M | |
| Cash From Financing | -$1.6M | -$24.3M | -$8.4M | -$276.9K | -$7.7M | |
| Free Cash Flow | -$7.6M | -$909.3K | -$2M | -$1.1M | -$898.5K | |
APXZF
Sector
Market Cap
$301M
$28.1M
Price % of 52-Week High
100%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
2.4%
-1.49%
1-Year Price Total Return
--
-17.13%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.30
200-day SMA
Sell
Level
$4.30
Bollinger Bands (100)
Sell
Level
4.3 - 4.3
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$4.30
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Neutral
Level
8.67
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$4.30
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.7346)
Buy
CA Score
(Annual)
Level (1.0875)
Buy
Beneish M-Score
(Annual)
Level (-2.3095)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.0014)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Carasent AB engages in the development of mission-critical software for the health and care sector. Its product portfolio includes electronic health record systems, advanced business intelligence tools, and a range of ecosystem services for healthcare operations. The company was founded in 2012 and is headquartered in Gothenburg, Sweden.
Stock Forecast FAQ
In the current month, APXZF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The APXZF average analyst price target in the past 3 months is --.
-
Where Will Carasent AB Stock Be In 1 Year?
According to analysts, the consensus estimate is that Carasent AB share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Carasent AB?
Analysts are divided on their view about Carasent AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Carasent AB is a Sell and believe this share price will rise from its current level to --.
-
What Is Carasent AB's Price Target?
The price target for Carasent AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is APXZF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Carasent AB is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of APXZF?
You can purchase shares of Carasent AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Carasent AB shares.
-
What Is The Carasent AB Share Price Today?
Carasent AB was last trading at $4.30 per share. This represents the most recent stock quote for Carasent AB. Yesterday, Carasent AB closed at $4.30 per share.
-
How To Buy Carasent AB Stock Online?
In order to purchase Carasent AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get APXZF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
APXZF
Sector
P/E ratio
705.48x
23.89x
PEG ratio
-0.37x
-0.01x
P/B ratio
3.43x
1.81x
Price / LTM sales
9.92x
1.59x
Growth Metrics
APXZF
Sector
Revenue growth
40.16%
4.62%
Earnings growth
377.03%
11.06%
Revenue (5-year growth)
36.75%
6.5%
Earnings forecast
--
-$0.21
Profitability
APXZF
Sector
Profitability FY 2024
$3M
$3.6M
Return on invested capital
0.48%
-31.84%
Return on assets
0.42%
-27.96%
Return on equity
0.5%
-37.63%
Earnings Date
Last Earnings Date
Dec
25
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
APXZF
Sector
Total cash
$18.4M
$26.4M
Short term investments
--
$25.7M
Total assets
$97M
$76.9M
Long term debt
$3.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
